Collectively, the antioxidant properties and insulin-sensitizing effects of SGLT2 inhibitors could disrupt the interplay between oxidative stress and insulin resistance in T2DM and serve as favorable therapeutic options. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.